Table 5.

Curcumin in clinical trials for metabolic and inflammatory disorders.

Status	Study Title	Conditions	Intervention	Phase	NCT Number
Completed	Micellar Curcumin and Metabolic Syndrome Biomarkers	Metabolic Syndrome, Protection Against	20 mg of curcumin at the beginning, after 3 and 6 weeks	Phase 2	NCT01925547
Completed	Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma	Endometrial Carcinoma	2 g daily for 2 weeks	Phase 2	NCT02017353
Completed	The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury	Neuropathic Pain, Depression, Cognitive Impairment	400 mg Baseline/3 months/6 months	Phase 3	NCT02099890
Completed with results	Oral Curcumin for Radiation Dermatitis	Radiation-induced Dermatitis, Breast cancer	2 g 3 times daily for 1 week	Phase 2/3	NCT01246973
Completed with results	Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients		2 g 3 times daily (~4–7 weeks)	Phase 2	NCT01042938
Completed with results	Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer (Curcumin-II)	Breast Carcinoma, Breast Carcinoma, Pain, Radiation-Induced Dermatitis,		Phase 2	NCT02556632